695 related articles for article (PubMed ID: 18957679)
1. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
Di Maio M; Daniele B; Gallo C; Perrone F
J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
[No Abstract] [Full Text] [Related]
2. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial design in hepatocellular carcinoma.
Johnson PJ; Billingham LJ
Best Pract Res Clin Gastroenterol; 2005 Feb; 19(1):119-27. PubMed ID: 15757808
[TBL] [Abstract][Full Text] [Related]
4. A 25-year review of sequential methodology in clinical studies.
Todd S
Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials.
Farrington P; Miller E
Methods Mol Med; 2003; 87():335-52. PubMed ID: 12958466
[No Abstract] [Full Text] [Related]
6. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
7. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
8. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
9. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
10. Adaptive design may hasten clinical trials.
Schmidt C
J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
[No Abstract] [Full Text] [Related]
11. A strategic framework for novel drug development in multiple myeloma.
Anderson KC; Hannah AL; Pazdur R; Farrell AT
Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
[No Abstract] [Full Text] [Related]
12. Critical issues in the design and implementation of clinical trials in hepatocellular carcinoma.
Johnson PJ
Expert Rev Anticancer Ther; 2003 Aug; 3(4):421-3. PubMed ID: 12934653
[No Abstract] [Full Text] [Related]
13. Statistics in clinical trials.
Green SJ; Pauler DK
Curr Oncol Rep; 2004 Jan; 6(1):36-41. PubMed ID: 14664759
[TBL] [Abstract][Full Text] [Related]
14. Commentary on 'designing phase II studies in cancer with time-to-event endpoints'.
Case D; Morgan T
Clin Trials; 2008; 5(3):222-3; discussion 223-4. PubMed ID: 18559410
[No Abstract] [Full Text] [Related]
15. [Clinical studies--what is the putting of the question?].
Guttenberger R
Strahlenther Onkol; 1999 Apr; 175 Suppl 1():14-6. PubMed ID: 10230452
[No Abstract] [Full Text] [Related]
16. "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials.
Penel N; Clisant S; Lefebvre JL; Adenis A
J Clin Oncol; 2009 Sep; 27(26):e105. PubMed ID: 19667257
[No Abstract] [Full Text] [Related]
17. Design of randomized controlled trials.
Stanley K
Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
[No Abstract] [Full Text] [Related]
18. Curtailed two-stage designs with two dependent binary endpoints.
Chen CM; Chi Y
Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma: the need for progress.
Thomas MB; Zhu AX
J Clin Oncol; 2005 May; 23(13):2892-9. PubMed ID: 15860847
[No Abstract] [Full Text] [Related]
20. An overview of clinical trials.
Rich K
J Vasc Nurs; 2004 Mar; 22(1):32-4. PubMed ID: 14981501
[No Abstract] [Full Text] [Related]
[Next] [New Search]
